CRITICAL LIMB ISCHEMIA TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Critical Limb Ischemia Treatment Market, By Drugs (Antihypertensive Agents, Antiplatelet Drugs, Antithrombotic Agents, Lipid-lowering Agents, and Others), By Route of administration (Oral and Parentral), By End User (Hospitals, Specialty Clinics , Ambulatory Surgery Centers, Nursing Homes, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

In June 2022, Cordis, a leader in cardiovascular technologies, launched the Radianz Radial Peripheral System for human use. This comprehensive system includes the PTA Catheter from SABERX RADIANZTM for enhanced treatment accessibility, the Vascular Stent System from SMART RADIANZTM to support long-term patency, and the BRITE TIP RADIANZTM Guiding Sheath. Together, these components form the integrated solution known as Radianz Radial Peripheral.
In June 2022, Royal Philips, a health technology company, announced new findings from the Tack Optimized Balloon Angioplasty (TOBA) II BTK clinical trial, revealing that their Philips endovascular system - Tack (4F) - the first USFDA-approved device of its kind, delivers lasting treatment benefits and improves quality of life for patients with critical limb ischemia (CLI).
In March 2022, LimFlow, a medtech company, completed enrollment in the PROMISE II U.S. pivotal trial for their innovative device aimed at preventing amputations in patients with chronic limb-threatening ischemia who have exhausted other treatment options